--- title: "Statin compliance predictors: branded to generic. | Sutter Health" description: "The majority of study patients switched from branded to generic agents were compliant with therapy in the first 6 months after switching." url: "https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734" --- 1. [Home](https://www.sutterhealth.org/) / 2. [Research](https://www.sutterhealth.org/research) / 3. [Research publications](https://www.sutterhealth.org/research/publications) / 4. Statin compliance predictors: branded to generic. # Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries. Romanelli RJ & Segal JB. _J Gen Intern Med. \[Epub ahead of print\]_ 2014-06-24 ## Abstract ****OBJECTIVES:**** To identify patient demographics and characteristics associated with compliance to statin therapy after switching from branded to generic agents ****DESIGN:**** Retrospective cohort study using electronic health records and pharmacy claims data from Sutter Health's ambulatory-care medical network ****PATIENTS:**** Managed-care beneficiaries, ≥ 18 years of age, who were switched from branded to generic statins between 1 January 2003 and 31 December 2012 MAIN MEASURES: Compliance was calculated as days of therapy dispensed divided by days from first to last generic prescription fill over 6 months, and was defined as a medication possession ratio ≥ 0.80. We used multivariable logistic regression to assess factors associated with compliance. Adjusted ORs and 95 % CI were generated. ****KEY RESULTS:**** We identified 5,156 patients who were switched from branded to generic statins; 73 % of patients were compliant in the 6 months after switching. After statistical adjustment, higher compliance was associated with each 10-year increase in age (OR: 1.13; 95 % CI: 1.07, 1.19; p < 0.001), receipt of a generic statin equivalent in potency to the prior branded statin (OR: 1.41; 95 % CI: 1.16, 1.70; p < 0.001), and compliance with prior branded statin (OR: 4.68; 95 % CI: 4.07, 5.39; p < 0.001). Lower compliance was seen among Hispanic patients compared to non-Hispanic white patients (OR: 0.68; 95 % CI: 0.52, 0.91; p = 0.009). Also, a switch to a higher potency generic statin, regardless of prior dose/potency, was negatively associated with compliance after switching (OR: 0.87; 95 % CI: 0.80, 0.94; p = 0.001). ****CONCLUSIONS:**** The majority of patients switched from branded to generic agents were compliant with therapy in the first 6 months after switching. The potential for non-compliance to generic statin therapy, particularly among younger or Hispanic patients or when dose/potency changes are made, should be considered prior to switching. For these patients, counseling or close monitoring may be required to optimize generic interchange. [PubMed abstract](http://www.ncbi.nlm.nih.gov/pubmed/24957381) ## Research topics - [Cardiovascular Diseases](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Cardiovascular+Diseases%5C%22%22) - [Disease Management](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Disease+Management%5C%22%22) - [Health Services](https://www.sutterhealth.org/research-search-results?query=%22%5C%22Health+Services%5C%22%22) ## Related publications [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) - Publication ### [Financial incentives and cholesterol levels.](https://www.sutterhealth.org/research/publications/financial-incentives-and-cholesterol-levels-1055312411) Lesser LI, McCormack JP. JAMA. 315(15):1657-8. doi: 10.1001/jama.2016.0309. 2016 Apr 19 - Publication ### [Compliance after switching from branded to generic statins.](https://www.sutterhealth.org/research/publications/compliance-switch-from-branded-to-generic-statins-1055312703) Romanelli RJ, Jukes T, Segal JB. Pharmacoepidemiol Drug Saf. doi: 10.1002/pds.3630. 2014 May 09 - Publication ### [Improving adherence to best-practice guidelines for venous thromboembolism risk assessment and prevention.](https://www.sutterhealth.org/research/publications/improving-adherence-to-best-practice-in-vte-1055312724) Schiro TA, Sakowski J, Romanelli RJ, Jukes T, Newman J, Hudnut A, Leonard T. Am J Health Syst Pharm. 68(22):2184-9. doi: 10.2146/ajhp110102. 2011 Nov 15 - Publication ### [Multivariate analysis of factors associated with persistent colesevelam treatment among patients with hypercholesterolemia.](https://www.sutterhealth.org/research/publications/factors-associated-with-persistent-colesevelam-tx-1055312600) Romanelli RJ, Leahy A, Jukes T, Ye X, Kang A, Ishisaka DY. Ann Pharmacother. 47(10):1247-52. doi: 10.1177/1060028013501804. 2013 Oct 01 - Publication ### [Using unlicensed health coaches to improve care for insured patients with diabetes and hypertension: patient and physician perspectives on recruitment and uptake.](https://www.sutterhealth.org/research/publications/using-health-coaches-dm-htn-1055312462) Dillon E, Panattoni L, Meehan A, Chuang J, Wilson C, Tai-Seale M. Popul Health Manag. \[Epub ahead of print\] 2015 Dec 16 [View all publications](https://www.sutterhealth.org/research-search-results?verticalKey=research_publication) ```json {"@context":"https://schema.org","@type":"MedicalOrganization","name":"Sutter Health","@id":"https://www.sutterhealth.org/#medicalorganization","url":"https://www.sutterhealth.org","logo":"https://www.sutterhealth.org/static/images/sutter-health-logo.svg","address":{"@type":"PostalAddress","streetAddress":"2200 River Plaza Drive","addressLocality":"Sacramento","addressRegion":"CA","postalCode":"95833","addressCountry":"US"},"areaServed":{"@type":"AdministrativeArea","name":"California"},"sameAs":["https://www.facebook.com/SutterHealth","https://www.instagram.com/sutterhealth/","https://x.com/SutterHealth","https://www.youtube.com/sutterhealth","https://www.linkedin.com/company/sutter-health","https://en.wikipedia.org/wiki/Sutter_Health"]} ``` ```json {"@context":"https://schema.org","@type":"BreadcrumbList","@id":"https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734#breadcrumblist","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://www.sutterhealth.org/"},{"@type":"ListItem","position":2,"name":"Research","item":"https://www.sutterhealth.org/research"},{"@type":"ListItem","position":3,"name":"Research publications","item":"https://www.sutterhealth.org/research/publications"},{"@type":"ListItem","position":4,"name":"Statin compliance predictors: branded to generic."}]} ``` ```json {"@context":"https://schema.org","@type":"MedicalScholarlyArticle","@id":"https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734#medicalscholarlyarticle","name":"Predictors of statin compliance after switching from branded to generic agents among managed-care beneficiaries.","headline":"Statin compliance predictors: branded to generic.","abstract":"OBJECTIVES: To identify patient demographics and characteristics associated with compliance to statin therapy after switching from branded to generic agents DESIGN: Retrospective cohort study using electronic health records and pharmacy claims data from Sutter Health's ambulatory-care medical network PATIENTS: Managed-care beneficiaries, ≥ 18 years of age, who were switched from branded to generic statins between 1 January 2003 and 31 December 2012 MAIN MEASURES: Compliance was calculated as days of therapy dispensed divided by days from first to last generic prescription fill over 6 months, and was defined as a medication possession ratio ≥ 0.80. We used multivariable logistic regression to assess factors associated with compliance. Adjusted ORs and 95 % CI were generated. KEY RESULTS: We identified 5,156 patients who were switched from branded to generic statins; 73 % of patients were compliant in the 6 months after switching. After statistical adjustment, higher compliance was associated with each 10-year increase in age (OR: 1.13; 95 % CI: 1.07, 1.19; p \u003c 0.001), receipt of a generic statin equivalent in potency to the prior branded statin (OR: 1.41; 95 % CI: 1.16, 1.70; p \u003c 0.001), and compliance with prior branded statin (OR: 4.68; 95 % CI: 4.07, 5.39; p \u003c 0.001). Lower compliance was seen among Hispanic patients compared to non-Hispanic white patients (OR: 0.68; 95 % CI: 0.52, 0.91; p = 0.009). Also, a switch to a higher potency generic statin, regardless of prior dose/potency, was negatively associated with compliance after switching (OR: 0.87; 95 % CI: 0.80, 0.94; p = 0.001). CONCLUSIONS: The majority of patients switched from branded to generic agents were compliant with therapy in the first 6 months after switching. The potential for non-compliance to generic statin therapy, particularly among younger or Hispanic patients or when dose/potency changes are made, should be considered prior to switching. For these patients, counseling or close monitoring may be required to optimize generic interchange.","description":"The majority of study patients switched from branded to generic agents were compliant with therapy in the first 6 months after switching.","keywords":["Cardiovascular Diseases","Disease Management","Health Services"],"datePublished":"2014-06-24","url":"https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734","inLanguage":"en-US","identifier":[{"@type":"PropertyValue","propertyID":"PMID","value":"24957381"}],"sameAs":["https://pubmed.ncbi.nlm.nih.gov/24957381/"],"isPartOf":{"@type":"Periodical","name":"J Gen Intern Med"},"author":[{"@type":"Person","name":"Romanelli RJ"},{"@type":"Person","name":"Segal JB"}],"sourceOrganization":{"@type":"MedicalOrganization","name":"Palo Alto Medical Foundation Research Institute"},"about":[{"@type":"DefinedTerm","name":"Cardiovascular Diseases","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Cardiovascular+Diseases%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Disease Management","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Disease+Management%22%5D%7D%5D&verticalKey=research_publication"},{"@type":"DefinedTerm","name":"Health Services","url":"https://www.sutterhealth.org/research-search-results?facets=%5B%7B%22i%22%3A%22c_researchTopics.name%22%2C%22v%22%3A%5B%22Health+Services%22%5D%7D%5D&verticalKey=research_publication"}],"mainEntityOfPage":{"@type":"WebPage","@id":"https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734","breadcrumb":{"@id":"https://www.sutterhealth.org/research/publications/statin-compliance-predictors-branded-to-generic-1055312734#breadcrumblist"}}} ```